share_log

迪哲医药:自愿披露关于舒沃哲一线治疗EGFR 20号外显子插入突变型晚期非小细胞肺癌获美国FDA突破性疗法认定的公告

Dizhe Pharmaceutical: Voluntary disclosure of the announcement that Schwarzhe's first-line treatment for EGFR 20 exon insertion mutant advanced non-small cell lung cancer was recognized as a breakthrough treatment by the US FDA

Sensex a share ·  Apr 7
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more